J.P. MORGAN Healthcare Conference

Meet AiCuris at J.P. Morgan 34th Annual Healthcare Conference 2016 January 11-14 in San Francisco, CA, USA. more ...


Holger Zimmermann elected as board member of BioDeutschland

The annual meeting of BioDeutschland took place in Hannover on Monday, 5th of October. Part of the meeting was also the election of a new board for the next two years. more ...


Release of BEAM Position Paper

The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) today announces the release of its position paper. more ...


IMI: Start of epidemiological study

The IMI-funded COMBACTE-MAGNET-consortium announced the start of a retrospective epidemiological study in autumn 2015 more ...


AiCuris’ Chair of the Scientific Advisory Board, Prof. Ruebsamen-Schaeff honored with “IUPAC Award”

Prof. Helga Rübsamen-Schaeff, founding CEO and as of March Chair of the Scientific Advisory Board of Wuppertal-based Biotech AiCuris has been honored with the "IUPAC 2015 Distinguished Women in Chemistry or Chemical Engineering Award". more ...


AiCuris & the BEAM Alliance

AiCuris is one of the founding members of the newly launched alliance of Biotechs of Europe innovating in Anti-Microbial Resistance”, called the BEAM Alliance. more ...


AiCuris strengthens its management / AiCuris stärkt sein Management

Dr. Manickam Rangaraju joined AiCuris on 1st May 2015 as new Head of Development, responsible for all preclinical and clinical activities of the company. Already one month before Dr. Alexander Birkmann had taken over the position as Head of Research. more ...


Press release of the University of Utrecht on behalf of COMBACTE-MAGNET

Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB). more ...


Change at the top of AiCuris / Wechsel an der Spitze von AiCuris

After 9 very successful years establishing and developing Wuppertal-based biotech company AiCuris, Prof. Dr. Helga Rübsamen-Schaeff will transition from her function as CEO to assume the role of Chair of the Board, as of March 1st 2015. more ...

If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
Management Assistant

AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com